Comprehensive Diabetes Care: LDL-C Screening
Description
The percentage of members 18-75 years of age with diabetes (type 1 and type 2) who received an LDL-C test during the measurement year.
The percentage of members 18-75 years of age with diabetes (type 1 and type 2) who received an LDL-C test during the measurement year.
The percentage of patients age 18 years or older with poorly controlled COPD, who are taking a long acting bronchodilator.
Proportion of ischemic stroke patients age 18 years or older for whom an initial NIHSS score is performed prior to any acute recanalization therapy (i.e., intra-venous (IV) thrombolytic (t-PA) therapy, or intra-arterial (IA) thrombolytic (t-PA) therapy, or mechanical endovascular reperfusion (MER) therapy) in patients undergoing recanalization therapy and documented in the medical record, or documented within 12 hours of arrival at the hospital emergency department in patients who do not undergo recanalization therapy.
Proportion of SAH and ICH stroke patients age 18 years or older for whom a severity measurement (i.e., Hunt and Hess Scale for SAH patients or ICH Score for ICH patients) is performed prior to surgical intervention (e.g., clipping, coiling, or any surgical intervention) in patients undergoing surgical intervention and documented in the medical record; OR, documented within 6 hours of arrival at the hospital emergency department in patients who do not undergo surgical intervention.
Proportion of subarachnoid hemorrhage (SAH) patients age 18 years and older for whom nimodipine treatment was administered within 24 hours of arrival at this hospital.
This is the sixth measure in a set of measures developed for Joint Commission Comprehensive Stroke Certification. Although it is not required that these measures are reported in conjunction with each other, The Joint Commission develops measures in sets in order to provide as comprehensive a view of quality for a particular clinical topic as possible.
The percentage of adolescents 13 years of age who had a screening for depression using a standardized tool.
The measure assesses whether the parent or caregiver completed a developmental screening tool meant to identify children at-risk for developmental, behavioral and social delays. Developmental screening is defined as a standardized tool that assesses the child’s risk for developmental, behavioral and social delays. The American Academy of Pediatrics recommends standardized screening using an approved screening tool as the best method of identifying children at risk for developmental, behavioral and/or social delays.
The percentage of patients aged 18 to75 years with a diagnosis of diabetes whose most recent HbA1c value is between 8 and 10 percent and who are taking metformin.
Medication Possession Ratio (MPR) for statin therapy in diabetic individuals over 18 years of age
The percentage of patients aged 18 to 75 with diagnosis of diabetes and hypertension or proteinuria who have a current fill for an angiotensin converting enzyme inhibitor (ACE-I) or angiotensin receptor blocker (ARB)